47 results
8-K
EX-99.1
PRME
Prime Medicine Inc
10 May 24
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
8:05am
for neuromuscular programs in 2024.
First Quarter 2024 Financial Results
Research and Development (R&D) Expenses: R&D expenses were $37.8 million … ; the initiation, timing, progress, and results of its research and development programs, preclinical studies and future clinical trials, and the release
PRE 14A
PRME
Prime Medicine Inc
19 Apr 24
Preliminary proxy
4:07pm
., a biotechnology company and a director and member of the research and development committee of Intercept Pharmaceuticals, Inc. He received his M.D. from … , participation in corporate and research and development strategy sessions, recruiting and interviewing activities, finding and establishing
8-K
EX-99.1
ezip8gxxh kt
1 Mar 24
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates
8:01am
8-K
yipz4jm79yjvvfh1yh
16 Feb 24
Entry into a Material Definitive Agreement
6:23am
424B5
x2ct4 913ltouyh
16 Feb 24
Prospectus supplement for primary offering
6:17am
FWP
e4pikmc o7f
14 Feb 24
Free writing prospectus
9:57pm
424B5
7adpc7r 6p0
14 Feb 24
Prospectus supplement for primary offering
5:27pm
8-K
EX-99.1
0671prnwc3 18
8 Jan 24
Regulation FD Disclosure
8:01am
S-3
5mdfhrj
3 Nov 23
Shelf registration
5:23pm
8-K
EX-99.1
0g8a7ktq 9nt7xhm
3 Nov 23
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
4:06pm
8-K
EX-99.1
u1iz7k ee
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
8-K
EX-99.2
rxnhn4d8j6chvd8b
7 Aug 23
Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates
4:04pm
8-K
EX-99.1
ygu6u7bbijv2r7qvu3
17 May 23
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
7:09am